person · Reporting owner

EMSTER KURT VON

Disclosed activity across 6 companies

Tapewire entity: 26596
SEC CIK: 0001252524

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
CRISPR Therapeutics AGCRSP · Entity 3852	Director	December 18, 2018	January 18, 2019
Iambic Therapeutics, Inc.IAM · Entity 184417	Director	October 14, 2026	October 14, 2026
Jasper Therapeutics, Inc.JSPR · Entity 7588	Director	July 31, 2026	August 04, 2026
Vaxcyte, Inc.PCVX · Entity 1164	Director	June 02, 2021	June 03, 2021
Vera Therapeutics, Inc.VERA · Entity 4358	Director	May 17, 2021	May 19, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

CRISPR Therapeutics AG

Report date December 18, 2018 · Filed January 18, 2019 · Amendment

Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common SharesSEC Table I · non-derivative	IndirectSee Footnote	1,171,268	Reported balance After 2018-12-18 transaction · row 1 Amendment: may correct only part of an earlier disclosure. 1 source row Row 1 · 2018-12-18 · Sale · Disposed 62,925 · Balance 1,171,268 F1: This amended Form 4 is being filed to correct the number of shares sold on December 18, 2018 and the number of shares beneficially owned following the transaction. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.18 to $30.62 per share, inclusive. F3: The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F4: Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI. F5: From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI and ABE to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: This amended Form 4 is being filed to correct the number of shares sold on December 18, 2018 and the number of shares beneficially owned following the transaction.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.18 to $30.62 per share, inclusive.

F3: The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein.

F4: Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI.

F5: From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI and ABE to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any.

Iambic Therapeutics, Inc.

Report date October 14, 2026 · Filed October 14, 2026

This filing explicitly reported no securities owned.

Jasper Therapeutics, Inc.

Report date July 31, 2026 · Filed August 04, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock Option (Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $0.63 · Expires 2036-07-31	Direct	7,500	Reported balance After 2026-07-31 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2026-07-31 · Grant · Acquired 7,500 · Balance 7,500 F1: Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders, which shall vest in full upon the first anniversary of the date of the grant, subject to the director's continued service through such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders, which shall vest in full upon the first anniversary of the date of the grant, subject to the director's continued service through such vesting date.

Vaxcyte, Inc.

Report date June 02, 2021 · Filed June 03, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Stock option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.49 · Expires 2031-06-01	Direct	15,000	Reported balance After 2021-06-02 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2021-06-02 · Grant · Acquired 15,000 · Balance 15,000 F1: The shares subject to the option will vest monthly and fully vest on the earlier of June 2, 2022 or the day prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date. F2: The Reporting Person is a member of Abingworth LLP ("ALLP"). ALLP provides advisory services to Abingworth Bioventures VI, LP ("ABV VI"). Under an agreement between the Reporting Person and ALLP, the Reporting Person is deemed to hold this Option and any shares of common stock issuable upon exercise of the Option, for the benefit of ABV VI, and must exercise the Option solely upon the direction of ALLP. F3: ABV VI may be deemed the indirect beneficial owner of the Option, and the Reporting Person may be deemed the indirect beneficial owner of the Option through his indirect interest in ABV VI. The Reporting Person disclaims beneficial ownership of the Option except to the extent, if any, of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person, ALLP, ABV VI or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to the option will vest monthly and fully vest on the earlier of June 2, 2022 or the day prior to the next annual meeting of stockholders, subject to the Reporting Person's continuous service through such date.

F2: The Reporting Person is a member of Abingworth LLP ("ALLP"). ALLP provides advisory services to Abingworth Bioventures VI, LP ("ABV VI"). Under an agreement between the Reporting Person and ALLP, the Reporting Person is deemed to hold this Option and any shares of common stock issuable upon exercise of the Option, for the benefit of ABV VI, and must exercise the Option solely upon the direction of ALLP.

F3: ABV VI may be deemed the indirect beneficial owner of the Option, and the Reporting Person may be deemed the indirect beneficial owner of the Option through his indirect interest in ABV VI. The Reporting Person disclaims beneficial ownership of the Option except to the extent, if any, of his pecuniary interest therein. This report shall not be deemed an admission that the Reporting Person, ALLP, ABV VI or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Vera Therapeutics, Inc.

Report date May 17, 2021 · Filed May 19, 2021

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	17,828	Reported balance After 2021-05-17 transaction · row 1 1 source row Row 1 · 2021-05-17 · Purchase · Acquired 17,828 · Balance 17,828 F1: The price reported is a weighted-average price. The shares were purchased at prices ranging from $11.60 to $12.25. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares purchased at each separate price.
Class A Common StockSEC Table I · non-derivative	IndirectSee footnote	2,960,231	Last balance in matching sequence After 2021-05-18 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 2 · 2021-05-18 · Conversion · Acquired 2,187,504 · Balance 2,187,504 F2: The Series C Preferred Stock automatically converted into Class A Common Stock on a 11.5869:1 basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on May 7, 2021) and had no expiration date. F3: The shares are held by Abingworth Bioventures 8, LP ("ABV 8"). Abingworth Bioventures 8 GP LP ("Abingworth GP") serves as the general partner of ABV 8. Abingworth General Partner 8 LLP serves as the general partner of Abingworth GP. ABV 8 (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner 8 LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by ABV 8. The Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a super majority vote, and no individual member has the sole control or voting power over the shares held by ABV 8. F4: From time to time, the investment committee may delegate investment and voting authority over certain securities held by the Abingworth Funds to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the reporting person, ABV 8 or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose. Row 3 · 2021-05-18 · Purchase · Acquired 772,727 · Balance 2,960,231 F3: The shares are held by Abingworth Bioventures 8, LP ("ABV 8"). Abingworth Bioventures 8 GP LP ("Abingworth GP") serves as the general partner of ABV 8. Abingworth General Partner 8 LLP serves as the general partner of Abingworth GP. ABV 8 (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner 8 LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by ABV 8. The Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a super majority vote, and no individual member has the sole control or voting power over the shares held by ABV 8. F4: From time to time, the investment committee may delegate investment and voting authority over certain securities held by the Abingworth Funds to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the reporting person, ABV 8 or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
Series C Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2021-05-18 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-05-18 · Conversion · Disposed 2,187,504 · Balance 0 F2: The Series C Preferred Stock automatically converted into Class A Common Stock on a 11.5869:1 basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on May 7, 2021) and had no expiration date. F3: The shares are held by Abingworth Bioventures 8, LP ("ABV 8"). Abingworth Bioventures 8 GP LP ("Abingworth GP") serves as the general partner of ABV 8. Abingworth General Partner 8 LLP serves as the general partner of Abingworth GP. ABV 8 (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner 8 LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by ABV 8. The Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a super majority vote, and no individual member has the sole control or voting power over the shares held by ABV 8. F4: From time to time, the investment committee may delegate investment and voting authority over certain securities held by the Abingworth Funds to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the reporting person, ABV 8 or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported is a weighted-average price. The shares were purchased at prices ranging from $11.60 to $12.25. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares purchased at each separate price.

F2: The Series C Preferred Stock automatically converted into Class A Common Stock on a 11.5869:1 basis (on an adjusted basis, after giving effect to the reverse stock split of the Class A Common Stock effected by the Issuer on May 7, 2021) and had no expiration date.

F3: The shares are held by Abingworth Bioventures 8, LP ("ABV 8"). Abingworth Bioventures 8 GP LP ("Abingworth GP") serves as the general partner of ABV 8. Abingworth General Partner 8 LLP serves as the general partner of Abingworth GP. ABV 8 (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner 8 LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by ABV 8. The Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a super majority vote, and no individual member has the sole control or voting power over the shares held by ABV 8.

F4: From time to time, the investment committee may delegate investment and voting authority over certain securities held by the Abingworth Funds to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. This report shall not be deemed an admission that the reporting person, ABV 8 or any other person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

CymaBay Therapeutics, Inc.

Report date March 22, 2024 · Filed March 22, 2024

Section 16 reporting ended · disclosed 2024-03-22. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2024-03-22 transaction · row 1 1 source row Row 1 · 2024-03-22 · Disposition to issuer · Disposed 90,000 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024 (the "Merger Agreement"), by and among CymaBay Therapeutics, Inc. ("CymaBay"), Gilead Sciences, Inc., a Delaware corporation ("Gilead"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead ("Purchaser"), among other things, Purchaser merged with and into the Company (the "Merger"). Accordingly, each outstanding share of CymaBay common stock was converted into the right to receive a cash payment equal to $32.50, less applicable withholding taxes.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.00 · Expires 2025-01-06	Direct	Reported balance After 2024-03-22 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-03-22 · Disposition to issuer · Disposed 9,000 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.97 · Expires 2025-06-23	Direct	Reported balance After 2024-03-22 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-03-22 · Disposition to issuer · Disposed 9,000 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.72 · Expires 2026-06-27	Direct	Reported balance After 2024-03-22 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-03-22 · Disposition to issuer · Disposed 9,000 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.50 · Expires 2027-06-27	Direct	Reported balance After 2024-03-22 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2024-03-22 · Disposition to issuer · Disposed 15,000 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.47 · Expires 2027-09-21	Direct	Reported balance After 2024-03-22 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2024-03-22 · Disposition to issuer · Disposed 7,500 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.69 · Expires 2028-01-23	Direct	Reported balance After 2024-03-22 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2024-03-22 · Disposition to issuer · Disposed 16,000 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.43 · Expires 2029-01-28	Direct	Reported balance After 2024-03-22 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2024-03-22 · Disposition to issuer · Disposed 27,705 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.05 · Expires 2030-05-14	Direct	Reported balance After 2024-03-22 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2024-03-22 · Disposition to issuer · Disposed 49,245 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.78 · Expires 2031-01-25	Direct	Reported balance After 2024-03-22 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2024-03-22 · Disposition to issuer · Disposed 32,000 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.94 · Expires 2032-01-24	Direct	Reported balance After 2024-03-22 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2024-03-22 · Disposition to issuer · Disposed 67,000 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.80 · Expires 2033-01-24	Direct	Reported balance After 2024-03-22 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2024-03-22 · Disposition to issuer · Disposed 25,000 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.
Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $22.85 · Expires 2034-01-23	Direct	Reported balance After 2024-03-22 transaction · row 13 Instrument identity requires review; Table II rows are not merged. 1 source row Row 13 · 2024-03-22 · Disposition to issuer · Disposed 14,010 · Balance 0 F2: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.

Filing footnotes · ownership attribution and instrument terms

F1: Pursuant to the Agreement and Plan of Merger, dated as of February 11, 2024 (the "Merger Agreement"), by and among CymaBay Therapeutics, Inc. ("CymaBay"), Gilead Sciences, Inc., a Delaware corporation ("Gilead"), and Pacific Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Gilead ("Purchaser"), among other things, Purchaser merged with and into the Company (the "Merger"). Accordingly, each outstanding share of CymaBay common stock was converted into the right to receive a cash payment equal to $32.50, less applicable withholding taxes.

F2: Pursuant to the Merger Agreement, each outstanding CymaBay stock option, whether or not vested, was cancelled and converted into the right to receive a cash payment equal to the product of (a) the excess of (i) $32.50 over (ii) the per share exercise price of such stock option, and (b) the total number of shares of CymaBay common stock subject to such stock option immediately prior to the effective time of the Merger, less applicable withholding taxes. Any outstanding CymaBay stock option with an exercise price equal to or greater than $32.50 was canceled for no consideration.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
December 18, 2018 Filed Dec 19, 2018 21:22 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	SaleCommon Shares	69,925	$29.70	$2,077,101.15	Disclosure SEC source: 0000905718-18-000981 · crisprfm4_dec172018.xml · nonDerivative · entry 2 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,164,268 F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.18 to $30.62 per share, inclusive. F2 · price: The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F3 · ownership.nature: Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI. F4 · ownership.nature: From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI and ABE to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document
December 18, 2018 Filed Jan 18, 2019 21:32 UTC Amendment	CRISPR Therapeutics AG CRSP · Entity 3852	SaleCommon Shares	62,925	$29.70	$1,869,168.25	Disclosure SEC source: 0000905718-19-000065 · crisprfm4a_dec192018.xml · nonDerivative · entry 1 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,171,268 F1 · shares: This amended Form 4 is being filed to correct the number of shares sold on December 18, 2018 and the number of shares beneficially owned following the transaction. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $29.18 to $30.62 per share, inclusive. F3 · price: The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F1 · balance_after: This amended Form 4 is being filed to correct the number of shares sold on December 18, 2018 and the number of shares beneficially owned following the transaction. F4 · ownership.nature: Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI. F5 · ownership.nature: From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI and ABE to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document
December 17, 2018 Filed Dec 19, 2018 16:18 UTC	CymaBay Therapeutics, Inc. CBAY · Entity 92768	SaleCommon Stock	88,889	$8.17	$726,223.13	Disclosure SEC source: 0000905718-18-000979 · cymabaytherafm4_dec172018.xml · nonDerivative · entry 1 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See footnotes Disclosed balance after: 184,528 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.03 to $8.51 per share, inclusive. F2 · price: The Reporting Person undertakes to provide to Cymabay Therapeutics, Inc. ("Issuer") any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F3 · ownership.nature: Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI. F4 · ownership.nature: From time to time, the investment committee may delegate investment and voting authority over certain securities held by the Abingworth Funds to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document
December 17, 2018 Filed Dec 19, 2018 21:22 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	SaleCommon Shares	3,009	$33.17	$99,797.10	Disclosure SEC source: 0000905718-18-000981 · crisprfm4_dec172018.xml · nonDerivative · entry 1 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,234,193 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $33.03 to $33.29 per share, inclusive. F2 · price: The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F3 · ownership.nature: Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI. F4 · ownership.nature: From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI and ABE to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document
June 15, 2018 Filed Jun 18, 2018 20:21 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	GrantStock Option (Right to Buy) · Derivative	15,000	$0.00 Strike: $59.31	$0.00	Disclosure SEC source: 0000905718-18-000569 · crisprfm4_jun152018.xml · derivative · entry 1 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Shares · 15,000 shares Expires 2028-06-15 F1 · derivative.exercise_date: This option was granted on June 15, 2018 with respect to 15,000 Common Shares with 100% of the shares vesting in 12 equal monthly installments beginning on May 30, 2018. Read SEC document
June 05, 2018 Filed Jun 7, 2018 19:30 UTC	CymaBay Therapeutics, Inc. CBAY · Entity 92768	OtherWarrant (right to buy) · Derivative	2,000	$0.00 Strike: $5.75	$0.00	Disclosure SEC source: 0000905718-18-000559 · cymabaytherafm4_jun52018.xml · derivative · entry 5 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005 Disclosed balance after: 0 Underlying: Common Stock · 2,000 shares Expires 2018-09-30 F1 · kind: On June 5, 2018, Kurt von Emster ("Reporting Person") on behalf of the Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005, exercised a warrant to purchase 2,000 shares of CymaBay Therapeutics, Inc. ("CBAY") common stock for $5.75 per share. The Reporting Person paid the exercise price on a cashless basis, resulting in CBAY's withholding of 920 of the warrant shares to pay the exercise price and issuing to the Reporting Person the remaining 1,080 shares. CBAY also paid $9.47 to the Reporting Person in lieu of a fractional share. Read SEC document
June 05, 2018 Filed Jun 7, 2018 19:30 UTC	CymaBay Therapeutics, Inc. CBAY · Entity 92768	SaleCommon Stock	920	$12.51	$11,509.20	Disclosure SEC source: 0000905718-18-000559 · cymabaytherafm4_jun52018.xml · nonDerivative · entry 2 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005 Disclosed balance after: 18,316 F1 · kind: On June 5, 2018, Kurt von Emster ("Reporting Person") on behalf of the Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005, exercised a warrant to purchase 2,000 shares of CymaBay Therapeutics, Inc. ("CBAY") common stock for $5.75 per share. The Reporting Person paid the exercise price on a cashless basis, resulting in CBAY's withholding of 920 of the warrant shares to pay the exercise price and issuing to the Reporting Person the remaining 1,080 shares. CBAY also paid $9.47 to the Reporting Person in lieu of a fractional share. Read SEC document
June 05, 2018 Filed Jun 7, 2018 19:30 UTC	CymaBay Therapeutics, Inc. CBAY · Entity 92768	OtherCommon Stock	2,000	$5.75	$11,500.00	Disclosure SEC source: 0000905718-18-000559 · cymabaytherafm4_jun52018.xml · nonDerivative · entry 1 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005 Disclosed balance after: 19,236 Read SEC document
June 05, 2018 Filed Jun 7, 2018 20:36 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	OtherWarrant (right to buy) · Derivative	2,000	$0.00 Strike: $5.75	$0.00	Disclosure SEC source: 0000905718-18-000554 · crispr-fm4_jun42018.xml · derivative · entry 5 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005 Disclosed balance after: 0 Underlying: Common Stock · 2,000 shares Expires 2018-09-30 Read SEC document
June 05, 2018 Filed Jun 7, 2018 20:36 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	SaleCommon Stock	920	$12.51	$11,509.20	Disclosure SEC source: 0000905718-18-000554 · crispr-fm4_jun42018.xml · nonDerivative · entry 2 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005 Disclosed balance after: 18,316 F1 · kind: On June 5, 2018, Kurt von Emster (the "Reporting Person") on behalf of the Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005, exercised a warrant to purchase 2,000 shares of CymaBay Therapeutics, Inc. ("CBAY") common stock for $5.75 per share. The Reporting Person paid the exercise price on a cashless basis, resulting in CBAY's withholding of 920 of the warrant shares to pay the exercise price and issuing to the Reporting Person the remaining 1,080 shares. CBAY also paid $9.47 to the Reporting Person in lieu of a fractional share. Read SEC document
June 05, 2018 Filed Jun 7, 2018 20:36 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	OtherCommon Stock	2,000	$5.75	$11,500.00	Disclosure SEC source: 0000905718-18-000554 · crispr-fm4_jun42018.xml · nonDerivative · entry 1 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005 Disclosed balance after: 19,236 Read SEC document
June 05, 2018 Filed Jun 11, 2018 08:42 UTC Amendment	CymaBay Therapeutics, Inc. CBAY · Entity 92768	OtherWarrant (right to buy) · Derivative	2,000	$0.00 Strike: $5.75	$0.00	Disclosure SEC source: 0000905718-18-000561 · cymabayfm4a_jun52018.xml · derivative · entry 5 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By The Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005 Disclosed balance after: 0 Underlying: Common Stock · 2,000 shares Expires 2018-09-30 Read SEC document
June 05, 2018 Filed Jun 11, 2018 08:42 UTC Amendment	CymaBay Therapeutics, Inc. CBAY · Entity 92768	SaleCommon Stock	920	$12.51	$11,509.20	Disclosure SEC source: 0000905718-18-000561 · cymabayfm4a_jun52018.xml · nonDerivative · entry 2 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005 Disclosed balance after: 18,316 F1 · kind: This amended Form 4 is being amended to correct the incorrect code used for acquisition of the warrant securities. On June 5, 2018, Kurt von Emster (the "Reporting Person") on behalf of the Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005, exercised a warrant to purchase 2,000 shares of CymaBay Therapeutics, Inc. ("CBAY") common stock for $5.75 per share. The Reporting Person paid the exercise price on a cashless basis, resulting in CBAY's withholding of 920 of the warrant shares to pay the exercise price and issuing to the Reporting Person the remaining 1,080 shares. CBAY also paid $9.47 to the Reporting Person in lieu of a fractional share. Read SEC document
June 05, 2018 Filed Jun 11, 2018 08:42 UTC Amendment	CymaBay Therapeutics, Inc. CBAY · Entity 92768	OtherCommon Stock	2,000	$5.75	$11,500.00	Disclosure SEC source: 0000905718-18-000561 · cymabayfm4a_jun52018.xml · nonDerivative · entry 1 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By the Konrad Hans von Emster III and Elizabeth F. von Emster Revocable Trust dated January 18, 2005 Disclosed balance after: 19,236 Read SEC document
May 14, 2018 Filed May 16, 2018 00:04 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	SaleCommon Shares	8,900	$52.20	$464,539.95	Disclosure SEC source: 0000905718-18-000518 · crispr-fm4_may112018.xml · nonDerivative · entry 9 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,237,202 F1 · kind: Kurt von Emster's (the "Reporting Person") pecuniary interest in Abingworth Bioventures VI LP's ("ABV VI") May 11, 2018 and May 14, 2018 sales of common stock of CRISPR Therapeutics AG ("Issuer") reported herein were matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of Reporting Person's pecuniary interest in Abingworth BioEquities Master Fund Limited's ("ABE") January 5, 2018 purchase of 65,934 shares of common stock of Issuer at a price of $22.75 per share. The Reporting Person has agreed to pay to Issuer the full amount of the Reporting Person's pecuniary interest in the profit realized in connection with the short-swing transactions, less transaction costs (rounded to the nearest dollar). F12 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.00 to $52.37 per share, inclusive. F13 · price: The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F2 · ownership.nature: Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI. F3 · ownership.nature: From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI and ABE to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document
May 14, 2018 Filed May 16, 2018 00:04 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	SaleCommon Shares	20,881	$52.93	$1,105,312.77	Disclosure SEC source: 0000905718-18-000518 · crispr-fm4_may112018.xml · nonDerivative · entry 8 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,246,102 F1 · kind: Kurt von Emster's (the "Reporting Person") pecuniary interest in Abingworth Bioventures VI LP's ("ABV VI") May 11, 2018 and May 14, 2018 sales of common stock of CRISPR Therapeutics AG ("Issuer") reported herein were matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of Reporting Person's pecuniary interest in Abingworth BioEquities Master Fund Limited's ("ABE") January 5, 2018 purchase of 65,934 shares of common stock of Issuer at a price of $22.75 per share. The Reporting Person has agreed to pay to Issuer the full amount of the Reporting Person's pecuniary interest in the profit realized in connection with the short-swing transactions, less transaction costs (rounded to the nearest dollar). F11 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.38 to $53.37 per share, inclusive. F13 · price: The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F2 · ownership.nature: Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI. F3 · ownership.nature: From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI and ABE to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document
May 14, 2018 Filed May 16, 2018 00:04 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	SaleCommon Shares	53,927	$53.86	$2,904,578.33	Disclosure SEC source: 0000905718-18-000518 · crispr-fm4_may112018.xml · nonDerivative · entry 7 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,266,983 F1 · kind: Kurt von Emster's (the "Reporting Person") pecuniary interest in Abingworth Bioventures VI LP's ("ABV VI") May 11, 2018 and May 14, 2018 sales of common stock of CRISPR Therapeutics AG ("Issuer") reported herein were matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of Reporting Person's pecuniary interest in Abingworth BioEquities Master Fund Limited's ("ABE") January 5, 2018 purchase of 65,934 shares of common stock of Issuer at a price of $22.75 per share. The Reporting Person has agreed to pay to Issuer the full amount of the Reporting Person's pecuniary interest in the profit realized in connection with the short-swing transactions, less transaction costs (rounded to the nearest dollar). F10 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $53.38 to $54.37 per share, inclusive. F13 · price: The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F2 · ownership.nature: Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI. F3 · ownership.nature: From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI and ABE to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document
May 14, 2018 Filed May 16, 2018 00:04 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	SaleCommon Shares	126,901	$54.99	$6,978,273.30	Disclosure SEC source: 0000905718-18-000518 · crispr-fm4_may112018.xml · nonDerivative · entry 6 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,320,910 F1 · kind: Kurt von Emster's (the "Reporting Person") pecuniary interest in Abingworth Bioventures VI LP's ("ABV VI") May 11, 2018 and May 14, 2018 sales of common stock of CRISPR Therapeutics AG ("Issuer") reported herein were matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of Reporting Person's pecuniary interest in Abingworth BioEquities Master Fund Limited's ("ABE") January 5, 2018 purchase of 65,934 shares of common stock of Issuer at a price of $22.75 per share. The Reporting Person has agreed to pay to Issuer the full amount of the Reporting Person's pecuniary interest in the profit realized in connection with the short-swing transactions, less transaction costs (rounded to the nearest dollar). F9 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $54.39 to $55.37 per share, inclusive. F13 · price: The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F2 · ownership.nature: Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI. F3 · ownership.nature: From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI and ABE to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document
May 14, 2018 Filed May 16, 2018 00:04 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	SaleCommon Shares	73,144	$55.72	$4,075,722.65	Disclosure SEC source: 0000905718-18-000518 · crispr-fm4_may112018.xml · nonDerivative · entry 5 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,447,811 F1 · kind: Kurt von Emster's (the "Reporting Person") pecuniary interest in Abingworth Bioventures VI LP's ("ABV VI") May 11, 2018 and May 14, 2018 sales of common stock of CRISPR Therapeutics AG ("Issuer") reported herein were matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of Reporting Person's pecuniary interest in Abingworth BioEquities Master Fund Limited's ("ABE") January 5, 2018 purchase of 65,934 shares of common stock of Issuer at a price of $22.75 per share. The Reporting Person has agreed to pay to Issuer the full amount of the Reporting Person's pecuniary interest in the profit realized in connection with the short-swing transactions, less transaction costs (rounded to the nearest dollar). F8 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $55.37 to $56.37 per share, inclusive. F13 · price: The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F2 · ownership.nature: Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI. F3 · ownership.nature: From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI and ABE to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document
May 14, 2018 Filed May 16, 2018 00:04 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	SaleCommon Shares	116,247	$56.90	$6,614,128.81	Disclosure SEC source: 0000905718-18-000518 · crispr-fm4_may112018.xml · nonDerivative · entry 4 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,520,955 F1 · kind: Kurt von Emster's (the "Reporting Person") pecuniary interest in Abingworth Bioventures VI LP's ("ABV VI") May 11, 2018 and May 14, 2018 sales of common stock of CRISPR Therapeutics AG ("Issuer") reported herein were matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of Reporting Person's pecuniary interest in Abingworth BioEquities Master Fund Limited's ("ABE") January 5, 2018 purchase of 65,934 shares of common stock of Issuer at a price of $22.75 per share. The Reporting Person has agreed to pay to Issuer the full amount of the Reporting Person's pecuniary interest in the profit realized in connection with the short-swing transactions, less transaction costs (rounded to the nearest dollar). F7 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $56.38 to $57.37 per share, inclusive. F13 · price: The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F2 · ownership.nature: Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI. F3 · ownership.nature: From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI and ABE to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document
May 11, 2018 Filed May 16, 2018 00:04 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	SaleCommon Shares	8,633	$51.73	$446,554.01	Disclosure SEC source: 0000905718-18-000518 · crispr-fm4_may112018.xml · nonDerivative · entry 3 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,637,202 F1 · kind: Kurt von Emster's (the "Reporting Person") pecuniary interest in Abingworth Bioventures VI LP's ("ABV VI") May 11, 2018 and May 14, 2018 sales of common stock of CRISPR Therapeutics AG ("Issuer") reported herein were matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of Reporting Person's pecuniary interest in Abingworth BioEquities Master Fund Limited's ("ABE") January 5, 2018 purchase of 65,934 shares of common stock of Issuer at a price of $22.75 per share. The Reporting Person has agreed to pay to Issuer the full amount of the Reporting Person's pecuniary interest in the profit realized in connection with the short-swing transactions, less transaction costs (rounded to the nearest dollar). F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.45 to $51.94 per share, inclusive. F13 · price: The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F2 · ownership.nature: Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI. F3 · ownership.nature: From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI and ABE to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document
May 11, 2018 Filed May 16, 2018 00:04 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	SaleCommon Shares	127,890	$52.46	$6,708,610.63	Disclosure SEC source: 0000905718-18-000518 · crispr-fm4_may112018.xml · nonDerivative · entry 2 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,645,835 F1 · kind: Kurt von Emster's (the "Reporting Person") pecuniary interest in Abingworth Bioventures VI LP's ("ABV VI") May 11, 2018 and May 14, 2018 sales of common stock of CRISPR Therapeutics AG ("Issuer") reported herein were matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of Reporting Person's pecuniary interest in Abingworth BioEquities Master Fund Limited's ("ABE") January 5, 2018 purchase of 65,934 shares of common stock of Issuer at a price of $22.75 per share. The Reporting Person has agreed to pay to Issuer the full amount of the Reporting Person's pecuniary interest in the profit realized in connection with the short-swing transactions, less transaction costs (rounded to the nearest dollar). F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.95 to $52.94 per share, inclusive. F13 · price: The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F2 · ownership.nature: Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI. F3 · ownership.nature: From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI and ABE to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document
May 11, 2018 Filed May 16, 2018 00:04 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	SaleCommon Shares	113,477	$53.36	$6,054,735.55	Disclosure SEC source: 0000905718-18-000518 · crispr-fm4_may112018.xml · nonDerivative · entry 1 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,773,725 F1 · kind: Kurt von Emster's (the "Reporting Person") pecuniary interest in Abingworth Bioventures VI LP's ("ABV VI") May 11, 2018 and May 14, 2018 sales of common stock of CRISPR Therapeutics AG ("Issuer") reported herein were matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of Reporting Person's pecuniary interest in Abingworth BioEquities Master Fund Limited's ("ABE") January 5, 2018 purchase of 65,934 shares of common stock of Issuer at a price of $22.75 per share. The Reporting Person has agreed to pay to Issuer the full amount of the Reporting Person's pecuniary interest in the profit realized in connection with the short-swing transactions, less transaction costs (rounded to the nearest dollar). F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $52.95 to $53.94 per share, inclusive. F13 · price: The Reporting Person undertakes to provide to Issuer any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F2 · ownership.nature: Shares are held by ABV VI. Abingworth LLP is the investment manager of ABV VI and has been delegated with all investment and dispositive power over the securities held by ABV VI. Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABV VI. F3 · ownership.nature: From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABV VI and ABE to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document
March 05, 2018 Filed Mar 7, 2018 16:19 UTC	CymaBay Therapeutics, Inc. CBAY · Entity 92768	SaleCommon Stock	13,353	$15.51	$207,105.03	Disclosure SEC source: 0000905718-18-000307 · cymabaytherafm4_mar52018.xml · nonDerivative · entry 1 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 273,417 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Abingworth Bioventures VI, LP ("ABV VI") and Abingworth BioEquities Master Fund Limited ("ABE") on September 29, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.50 to $15.57 per share, inclusive. Kurt von Emster (the "Reporting Person") undertakes to provide to CymaBay Therapeutics, Inc. ("CymaBay"), any security holder of CymaBay, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F3 · ownership.nature: Shares are held by ABV VI and ABE, (ABE together with ABV VI, the "Abingworth Funds"). Abingworth LLP ("Abingworth") is the investment manager of the Abingworth Funds and has been delegated with all investment and dispositive power over the securities held by the Abingworth Funds. The Reporting Person is a member of the investment committee of Abingworth, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth. F4 · ownership.nature: From time to time, the investment committee may delegate investment and voting authority over certain securities held by the Abingworth Funds to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document
February 15, 2018 Filed Feb 20, 2018 16:08 UTC	CymaBay Therapeutics, Inc. CBAY · Entity 92768	SaleCommon Stock	68,712	$14.49	$995,636.88	Disclosure SEC source: 0000905718-18-000263 · cymabaytherafm4_feb15018.xml · nonDerivative · entry 1 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 286,770 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Abingworth Bioventures VI, LP ("ABV VI") and Abingworth BioEquities Master Fund Limited ("ABE") on September 29, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.53 to $14.87 per share, inclusive. Kurt von Emster (the "Reporting Person") undertakes to provide to CymaBay Therapeutics, Inc. ("CymaBay"), any security holder of CymaBay, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F3 · ownership.nature: Shares are held by ABV VI and ABE, (ABE together with ABV VI, the "Abingworth Funds"). Abingworth LLP ("Abingworth") is the investment manager of the Abingworth Funds and has been delegated with all investment and dispositive power over the securities held by the Abingworth Funds. The Reporting Person is a member of the investment committee of Abingworth, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth. F4 · ownership.nature: From time to time, the investment committee may delegate investment and voting authority over certain securities held by the Abingworth Funds to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document
February 14, 2018 Filed Feb 15, 2018 16:12 UTC	CymaBay Therapeutics, Inc. CBAY · Entity 92768	SaleCommon Stock	162,979	$16.69	$2,720,119.51	Disclosure SEC source: 0000905718-18-000256 · cymabaytherafm4_feb13018.xml · nonDerivative · entry 2 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 355,482 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Abingworth Bioventures VI, LP ("ABV VI") and Abingworth BioEquities Master Fund Limited ("ABE") on September 29, 2017. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.50 to $14.08 per share, inclusive. Reporting Person undertakes to provide to CymaBay any security holder of CymaBay, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F3 · ownership.nature: Shares are held by ABV VI and ABE, (ABE together with ABV VI, the "Abingworth Funds"). Abingworth LLP ("Abingworth") is the investment manager of the Abingworth Funds and has been delegated with all investment and dispositive power over the securities held by the Abingworth Funds. The Reporting Person is a member of the investment committee of Abingworth, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth. F4 · ownership.nature: From time to time, the investment committee may delegate investment and voting authority over certain securities held by the Abingworth Funds to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document
February 14, 2018 Filed Feb 16, 2018 14:44 UTC Amendment	CymaBay Therapeutics, Inc. CBAY · Entity 92768	SaleCommon Stock	162,979	$13.69	$2,231,182.51	Disclosure SEC source: 0000905718-18-000260 · cymabaytherafm4am1_feb14018.xml · nonDerivative · entry 1 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 355,482 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Abingworth Bioventures VI, LP ("ABV VI") and Abingworth BioEquities Master Fund Limited ("ABE") on September 29, 2017. F2 · price: This amendment is being filed to correct the sale price of the securities. The sale price of the securities was misstated on Kurt von Emster's (the "Reporting Person") original Form 4 filed with the Securities and Exchange Commission on February 15, 2018. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.50 to $14.08 per share, inclusive. The Reporting Person undertakes to provide to CymaBay Therapeutics, Inc. ("CymaBay"), any security holder of CymaBay, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F3 · ownership.nature: Shares are held by ABV VI and ABE, (ABE together with ABV VI, the "Abingworth Funds"). Abingworth LLP ("Abingworth") is the investment manager of the Abingworth Funds and has been delegated with all investment and dispositive power over the securities held by the Abingworth Funds. The Reporting Person is a member of the investment committee of Abingworth, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth. F4 · ownership.nature: From time to time, the investment committee may delegate investment and voting authority over certain securities held by the Abingworth Funds to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document
February 13, 2018 Filed Feb 15, 2018 16:12 UTC	CymaBay Therapeutics, Inc. CBAY · Entity 92768	SaleCommon Stock	55,078	$13.51	$744,103.78	Disclosure SEC source: 0000905718-18-000256 · cymabaytherafm4_feb13018.xml · nonDerivative · entry 1 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 518,461 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Abingworth Bioventures VI, LP ("ABV VI") and Abingworth BioEquities Master Fund Limited ("ABE") on September 29, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.50 to $13.75 per share, inclusive. Kurt von Emster (the "Reporting Person") undertakes to provide to CymaBay Therapeutics, Inc. ("CymaBay"), any security holder of CymaBay, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F3 · ownership.nature: Shares are held by ABV VI and ABE, (ABE together with ABV VI, the "Abingworth Funds"). Abingworth LLP ("Abingworth") is the investment manager of the Abingworth Funds and has been delegated with all investment and dispositive power over the securities held by the Abingworth Funds. The Reporting Person is a member of the investment committee of Abingworth, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth. F4 · ownership.nature: From time to time, the investment committee may delegate investment and voting authority over certain securities held by the Abingworth Funds to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document
February 07, 2018 Filed Feb 9, 2018 16:17 UTC	CymaBay Therapeutics, Inc. CBAY · Entity 92768	SaleCommon Stock	40,763	$12.35	$503,423.05	Disclosure SEC source: 0000905718-18-000117 · cymabaytherafm4_feb72018.xml · nonDerivative · entry 1 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 419,693 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Abingworth Bioventures VI, LP ("ABV VI") and Abingworth BioEquities Master Fund Limited ("ABE") on September 29, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.10 to $12.73 per share, inclusive. Kurt von Emster (the "Reporting Person") undertakes to provide to CymaBay Therapeutics, Inc. ("CymaBay"), any security holder of CymaBay, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F3 · ownership.nature: Shares are held by ABV VI and ABE, (ABE together with ABV VI, the "Abingworth Funds"). Abingworth LLP ("Abingworth") is the investment manager of the Abingworth Funds and has been delegated with all investment and dispositive power over the securities held by the Abingworth Funds. The Reporting Person is a member of the investment committee of Abingworth, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth. F4 · ownership.nature: From time to time, the investment committee may delegate investment and voting authority over certain securities held by the Abingworth Funds to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document
February 05, 2018 Filed Feb 7, 2018 16:20 UTC	CymaBay Therapeutics, Inc. CBAY · Entity 92768	SaleCommon Stock	18,831	$12.14	$228,608.34	Disclosure SEC source: 0000905718-18-000115 · cymabaytherafm4_feb52018.xml · nonDerivative · entry 1 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 460,456 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Abingworth Bioventures VI, LP ("ABV VI") and Abingworth BioEquities Master Fund Limited ("ABE") on September 29, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.10 to $12.30 per share, inclusive. Kurt von Emster (the "Reporting Person") undertakes to provide to CymaBay Therapeutics, Inc. ("CymaBay"), any security holder of CymaBay, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F3 · ownership.nature: Shares are held by ABV VI and ABE, (ABE together with ABV VI, the "Abingworth Funds"). Abingworth LLP ("Abingworth") is the investment manager of the Abingworth Funds and has been delegated with all investment and dispositive power over the securities held by the Abingworth Funds. The Reporting Person is a member of the investment committee of Abingworth, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth. F4 · ownership.nature: From time to time, the investment committee may delegate investment and voting authority over certain securities held by the Abingworth Funds to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document
February 02, 2018 Filed Feb 5, 2018 16:07 UTC	CymaBay Therapeutics, Inc. CBAY · Entity 92768	SaleCommon Stock	2,000	$12.11	$24,220.00	Disclosure SEC source: 0000905718-18-000111 · cymabaytherafm4_feb12018.xml · nonDerivative · entry 2 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 479,287 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Abingworth Bioventures VI, LP ("ABV VI") and Abingworth BioEquities Master Fund Limited ("ABE") on September 29, 2017. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.10 to $12.14 per share, inclusive. Reporting Person undertakes to provide to CymaBay any security holder of CymaBay, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F3 · ownership.nature: Shares are held by ABV VI and ABE, (ABE together with ABV VI, the "Abingworth Funds"). Abingworth LLP ("Abingworth") is the investment manager of the Abingworth Funds and has been delegated with all investment and dispositive power over the securities held by the Abingworth Funds. The Reporting Person is a member of the investment committee of Abingworth, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth. F4 · ownership.nature: From time to time, the investment committee may delegate investment and voting authority over certain securities held by the Abingworth Funds to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document
February 01, 2018 Filed Feb 5, 2018 16:07 UTC	CymaBay Therapeutics, Inc. CBAY · Entity 92768	SaleCommon Stock	88,098	$12.15	$1,070,390.70	Disclosure SEC source: 0000905718-18-000111 · cymabaytherafm4_feb12018.xml · nonDerivative · entry 1 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 481,287 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Abingworth Bioventures VI, LP ("ABV VI") and Abingworth BioEquities Master Fund Limited ("ABE") on September 29, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.10 to $12.40 per share, inclusive. Kurt von Emster (the "Reporting Person") undertakes to provide to CymaBay Therapeutics, Inc. ("CymaBay"), any security holder of CymaBay, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F3 · ownership.nature: Shares are held by ABV VI and ABE, (ABE together with ABV VI, the "Abingworth Funds"). Abingworth LLP ("Abingworth") is the investment manager of the Abingworth Funds and has been delegated with all investment and dispositive power over the securities held by the Abingworth Funds. The Reporting Person is a member of the investment committee of Abingworth, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth. F4 · ownership.nature: From time to time, the investment committee may delegate investment and voting authority over certain securities held by the Abingworth Funds to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document
January 31, 2018 Filed Feb 1, 2018 16:29 UTC	CymaBay Therapeutics, Inc. CBAY · Entity 92768	SaleCommon Stock	12,300	$12.23	$150,429.00	Disclosure SEC source: 0000905718-18-000096 · cymabaytherafm4_jan302018.xml · nonDerivative · entry 2 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 569,385 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Abingworth Bioventures VI, LP ("ABV VI") and Abingworth BioEquities Master Fund Limited ("ABE") on September 29, 2017. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.10 to $12.49 per share, inclusive. Reporting Person undertakes to provide to CymaBay any security holder of CymaBay, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F3 · ownership.nature: Shares are held by ABV VI and ABE, (ABE together with ABV VI, the "Abingworth Funds"). Abingworth LLP ("Abingworth") is the investment manager of the Abingworth Funds and has been delegated with all investment and dispositive power over the securities held by the Abingworth Funds. The Reporting Person is a member of the investment committee of Abingworth, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth. F4 · ownership.nature: From time to time, the investment committee may delegate investment and voting authority over certain securities held by the Abingworth Funds to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document
January 30, 2018 Filed Feb 1, 2018 16:29 UTC	CymaBay Therapeutics, Inc. CBAY · Entity 92768	SaleCommon Stock	85,339	$12.22	$1,042,842.58	Disclosure SEC source: 0000905718-18-000096 · cymabaytherafm4_jan302018.xml · nonDerivative · entry 1 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 581,685 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Abingworth Bioventures VI, LP ("ABV VI") and Abingworth BioEquities Master Fund Limited ("ABE") on September 29, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.10 to $12.55 per share, inclusive. Kurt von Emster (the "Reporting Person") undertakes to provide to CymaBay Therapeutics, Inc. ("CymaBay"), any security holder of CymaBay, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F3 · ownership.nature: Shares are held by ABV VI and ABE, (ABE together with ABV VI, the "Abingworth Funds"). Abingworth LLP ("Abingworth") is the investment manager of the Abingworth Funds and has been delegated with all investment and dispositive power over the securities held by the Abingworth Funds. The Reporting Person is a member of the investment committee of Abingworth, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth. F4 · ownership.nature: From time to time, the investment committee may delegate investment and voting authority over certain securities held by the Abingworth Funds to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document
January 25, 2018 Filed Jan 26, 2018 20:40 UTC	CymaBay Therapeutics, Inc. CBAY · Entity 92768	SaleCommon Stock	39,438	$12.18	$480,354.84	Disclosure SEC source: 0000905718-18-000074 · cymabaytherafm4_jan252018.xml · nonDerivative · entry 1 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 667,024 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Abingworth Bioventures VI, LP ("ABV VI") and Abingworth BioEquities Master Fund Limited ("ABE") on September 29, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $12.10 to $12.32 per share, inclusive. Kurt von Emster (the "Reporting Person") undertakes to provide to CymaBay Therapeutics, Inc. ("CymaBay"), any security holder of CymaBay, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F3 · ownership.nature: Shares are held by ABV VI and ABE, (ABE together with ABV VI, the "Abingworth Funds"). Abingworth LLP ("Abingworth") is the investment manager of the Abingworth Funds and has been delegated with all investment and dispositive power over the securities held by the Abingworth Funds. The Reporting Person is a member of the investment committee of Abingworth, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth. F4 · ownership.nature: From time to time, the investment committee may delegate investment and voting authority over certain securities held by the Abingworth Funds to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document
January 24, 2018 Filed Jan 26, 2018 20:40 UTC	CymaBay Therapeutics, Inc. CBAY · Entity 92768	GrantStock Option (right to buy) · Derivative	16,000	$0.00 Strike: $11.69	$0.00	Disclosure SEC source: 0000905718-18-000074 · cymabaytherafm4_jan252018.xml · derivative · entry 4 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Underlying: Common Stock · 16,000 shares Expires 2028-01-23 F5 · derivative.exercise_date: The option vests as to 1/12 of the underlying shares monthly beginning February 1, 2018. Read SEC document
January 22, 2018 Filed Jan 24, 2018 16:02 UTC	CymaBay Therapeutics, Inc. CBAY · Entity 92768	SaleCommon Stock	138,253	$10.40	$1,437,831.20	Disclosure SEC source: 0000905718-18-000070 · cymabaytherafm4_jan222018.xml · nonDerivative · entry 1 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 706,462 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Abingworth Bioventures VI, LP ("ABV VI") and Abingworth BioEquities Master Fund Limited ("ABE") on September 29, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.20 to $10.59 per share, inclusive. Kurt von Emster (the "Reporting Person") undertakes to provide to CymaBay Therapeutics, Inc. ("CymaBay"), any security holder of CymaBay, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F3 · ownership.nature: Shares are held by ABV VI and ABE, (ABE together with ABV VI, the "Abingworth Funds"). Abingworth LLP ("Abingworth") is the investment manager of the Abingworth Funds and has been delegated with all investment and dispositive power over the securities held by the Abingworth Funds. The Reporting Person is a member of the investment committee of Abingworth, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth. F4 · ownership.nature: From time to time, the investment committee may delegate investment and voting authority over certain securities held by the Abingworth Funds to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document
January 19, 2018 Filed Jan 22, 2018 17:26 UTC	CymaBay Therapeutics, Inc. CBAY · Entity 92768	SaleCommon Stock	130,584	$10.25	$1,338,486.00	Disclosure SEC source: 0000905718-18-000064 · cymabaytherafm4_jan182018.xml · nonDerivative · entry 2 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 844,715 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Abingworth Bioventures VI, LP ("ABV VI") and Abingworth BioEquities Master Fund Limited ("ABE") on September 29, 2017. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.20 to $10.46 per share, inclusive. Reporting Person undertakes to provide to CymaBay, any security holder of CymaBay, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F3 · ownership.nature: Shares are held by ABV VI and ABE, (ABE together with ABV VI, the "Abingworth Funds"). Abingworth LLP ("Abingworth") is the investment manager of the Abingworth Funds and has been delegated with all investment and dispositive power over the securities held by the Abingworth Funds. The Reporting Person is a member of the investment committee of Abingworth, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth. F4 · ownership.nature: From time to time, the investment committee may delegate investment and voting authority over certain securities held by the Abingworth Funds to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document
January 18, 2018 Filed Jan 22, 2018 17:26 UTC	CymaBay Therapeutics, Inc. CBAY · Entity 92768	SaleCommon Stock	13,632	$10.21	$139,182.72	Disclosure SEC source: 0000905718-18-000064 · cymabaytherafm4_jan182018.xml · nonDerivative · entry 1 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnotes Disclosed balance after: 975,299 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Abingworth Bioventures VI, LP ("ABV VI") and Abingworth BioEquities Master Fund Limited ("ABE") on September 29, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.20 to $10.24 per share, inclusive. Kurt von Emster (the "Reporting Person") undertakes to provide to CymaBay Therapeutics, Inc. ("CymaBay"), any security holder of CymaBay, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F3 · ownership.nature: Shares are held by ABV VI and ABE, (ABE together with ABV VI, the "Abingworth Funds"). Abingworth LLP ("Abingworth") is the investment manager of the Abingworth Funds and has been delegated with all investment and dispositive power over the securities held by the Abingworth Funds. The Reporting Person is a member of the investment committee of Abingworth, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth. F4 · ownership.nature: From time to time, the investment committee may delegate investment and voting authority over certain securities held by the Abingworth Funds to employees of Abingworth subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document
January 05, 2018 Filed Jan 9, 2018 16:34 UTC	CymaBay Therapeutics, Inc. CBAY · Entity 92768	SaleCommon Stock	4,300	$10.21	$43,903.00	Disclosure SEC source: 0000905718-18-000045 · cymabaytherafm4_jan52018.xml · nonDerivative · entry 1 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 988,931 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Abingworth Bioventures VI, LP ("ABV VI") and Abingworth BioEquities Master Fund Limited ("ABE") on September 29, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.20 to $10.24 per share, inclusive. Kurt von Emster (the "Reporting Person") undertakes to provide to CymaBay Therapeutics, Inc. ("CymaBay"), any security holder of CymaBay, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F3 · ownership.nature: Shares are held by ABV VI and ABE, (ABE together with ABV VI, the "Abingworth Funds"). Abingworth LLP ("Abingworth") is the investment manager of the Abingworth Funds and has been delegated with all investment and dispositive power over the securities held by the Abingworth Funds. The Reporting Person is a member of the investment committee of Abingworth, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document
January 05, 2018 Filed Jan 9, 2018 21:39 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	SaleCommon Shares	92,337	$26.96	$2,489,405.52	Disclosure SEC source: 0000905718-18-000047 · crisprfm4_jan52018.xml · nonDerivative · entry 1 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,821,268 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Abingworth Bioventures VI, LP ("Abingworth") on May 15, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.50 to $28.35 per share, inclusive. Kurt von Emster (the "Reporting Person") undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F3 · ownership.nature: These shares are held by Abingworth. Abingworth Bioventures VI GP LP ("Abingworth GP") serves as the general partner of Abingworth. Abingworth General Partner VI LLP, serves as the general partner of Abingworth GP. Abingworth (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VI LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by Abingworth. The Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document
January 05, 2018 Filed Jan 12, 2018 02:00 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	PurchaseCommon Shares	65,934	$22.75	$1,499,998.50	Disclosure SEC source: 0000905718-18-000054 · crisprabefm4_jan52018.xml · nonDerivative · entry 1 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,887,202 F1 · ownership.nature: Shares are held by Abingworth Bioequities Master Fund Limited ("ABE"). Abingworth LLP is the investment manager of ABE and has been delegated with all investment and dispositive power over the securities held by ABE. The Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by ABE. From time to time, the investment committee may delegate investment and voting authority over certain securities held by ABE to employees of Abingworth LLP subject to the supervision and oversight of the investment committee, including any limits on such authority imposed by the investment committee in its discretion and the right of the investment committee to revoke such authority at any time. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein, if any. Read SEC document
January 02, 2018 Filed Jan 4, 2018 22:29 UTC	CRISPR Therapeutics AG CRSP · Entity 3852	SaleCommon Shares	37,754	$26.76	$1,010,123.37	Disclosure SEC source: 0000905718-18-000020 · crisprfm4_jan22018.xml · nonDerivative · entry 1 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,913,605 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Abingworth Bioventures VI, LP ("Abingworth") on May 15, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.50 to $27.36 per share, inclusive. Kurt von Emster (the "Reporting Person") undertakes to provide to CRISPR Therapeutics AG, any security holder of CRISPR Therapeutics AG, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F3 · ownership.nature: These shares are held by Abingworth. Abingworth Bioventures VI GP LP ("Abingworth GP") serves as the general partner of Abingworth. Abingworth General Partner VI LLP, serves as the general partner of Abingworth GP. Abingworth (acting by its general partner Abingworth GP, acting by its general partner Abingworth General Partner VI LLP) has delegated to Abingworth LLP, all investment and dispositive power over the securities held by Abingworth. The Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document
December 22, 2017 Filed Dec 27, 2017 16:08 UTC	CymaBay Therapeutics, Inc. CBAY · Entity 92768	SaleCommon Stock	173,192	$9.41	$1,629,303.74	Disclosure SEC source: 0000905718-17-001042 · cymabaytherafm4_dec222017.xml · nonDerivative · entry 1 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 993,231 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Abingworth Bioventures VI, LP ("ABV VI") and Abingworth BioEquities Master Fund Limited ("ABE") on September 29, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.25 to $9.7760 per share, inclusive. Kurt von Emster (the "Reporting Person") undertakes to provide to CymaBay Therapeutics, Inc. ("CymaBay"), any security holder of CymaBay, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F3 · ownership.nature: Shares are held by ABV VI and ABE, (ABE together with ABV VI, the "Abingworth Funds"). Abingworth LLP ("Abingworth") is the investment manager of the Abingworth Funds and has been delegated with all investment and dispositive power over the securities held by the Abingworth Funds. The Reporting Person is a member of the investment committee of Abingworth, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document
November 10, 2017 Filed Nov 14, 2017 17:48 UTC	CymaBay Therapeutics, Inc. CBAY · Entity 92768	SaleCommon Stock	50,048	$9.26	$463,379.42	Disclosure SEC source: 0000905718-17-000974 · cymabaytherafm4_111017.xml · nonDerivative · entry 1 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,166,423 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Abingworth Bioventures VI, LP ("ABV VI") and Abingworth BioEquities Master Fund Limited ("ABE") on September 29, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.25 to $9.30 per share, inclusive. Kurt von Emster (the "Reporting Person") undertakes to provide to CymaBay Therapeutics, Inc. ("CymaBay"), any security holder of CymaBay, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F3 · ownership.nature: Shares are held by ABV VI and ABE, (ABE together with ABV VI, the "Abingworth Funds"). Abingworth LLP ("Abingworth") is the investment manager of the Abingworth Funds and has been delegated with all investment and dispositive power over the securities held by the Abingworth Funds. The Reporting Person is a member of the investment committee of Abingworth, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document
November 01, 2017 Filed Nov 3, 2017 16:52 UTC	CymaBay Therapeutics, Inc. CBAY · Entity 92768	SaleCommon Stock	4,320	$9.25	$39,979.44	Disclosure SEC source: 0000905718-17-000942 · cymabaytherafm4_nov12017.xml · nonDerivative · entry 1 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,216,471 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Abingworth Bioventures VI, LP ("ABV VI") and Abingworth BioEquities Master Fund Limited ("ABE") on September 29, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.25 to $9.32 per share, inclusive. Kurt von Emster (the "Reporting Person") undertakes to provide to CymaBay Therapeutics, Inc. ("CymaBay"), any security holder of CymaBay, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F3 · ownership.nature: Shares are held by ABV VI and ABE, (ABE together with ABV VI, the "Abingworth Funds"). Abingworth LLP ("Abingworth") is the investment manager of the Abingworth Funds and has been delegated with all investment and dispositive power over the securities held by the Abingworth Funds. The Reporting Person is a member of the investment committee of Abingworth, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document
October 31, 2017 Filed Nov 1, 2017 16:39 UTC	CymaBay Therapeutics, Inc. CBAY · Entity 92768	SaleCommon Stock	52,573	$9.27	$487,351.71	Disclosure SEC source: 0000905718-17-000938 · cymabaytherafm4_oct302017.xml · nonDerivative · entry 2 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,220,791 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Abingworth Bioventures VI, LP ("ABV VI") and Abingworth BioEquities Master Fund Limited ("ABE") on September 29, 2017. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.25 to $9.37 per share, inclusive. Reporting Person undertakes to provide to CymaBay, any security holder of CymaBay, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F3 · ownership.nature: Shares are held by ABV VI and ABE, (ABE together with ABV VI the "Abingworth Funds"). Abingworth LLP ("Abingworth") is the investment manager of the Abingworth Funds and has been delegated with all investment and dispositive power over the securities held by the Abingworth Funds. The Reporting Person is a member of the investment committee of Abingworth, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document
October 30, 2017 Filed Nov 1, 2017 16:39 UTC	CymaBay Therapeutics, Inc. CBAY · Entity 92768	SaleCommon Stock	6,636	$9.26	$61,449.36	Disclosure SEC source: 0000905718-17-000938 · cymabaytherafm4_oct302017.xml · nonDerivative · entry 1 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,273,364 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Abingworth Bioventures VI, LP ("ABV VI") and Abingworth BioEquities Master Fund Limited ("ABE") on September 29, 2017. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.25 to $9.35 per share, inclusive. Kurt von Emster (the "Reporting Person") undertakes to provide to CymaBay Therapeutics, Inc. ("CymaBay"), any security holder of CymaBay, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F3 · ownership.nature: Shares are held by ABV VI and ABE, (ABE together with ABV VI the "Abingworth Funds"). Abingworth LLP ("Abingworth") is the investment manager of the Abingworth Funds and has been delegated with all investment and dispositive power over the securities held by the Abingworth Funds. The Reporting Person is a member of the investment committee of Abingworth, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document
October 03, 2017 Filed Oct 4, 2017 16:02 UTC	CymaBay Therapeutics, Inc. CBAY · Entity 92768	SaleCommon Stock	70,940	$7.81	$554,041.40	Disclosure SEC source: 0000905718-17-000867 · cymabaytherafm4_oct22017.xml · nonDerivative · entry 2 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,280,000 F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.61 to $8.02 per share, inclusive. Reporting Person undertakes to provide to CymaBay, any security holder of CymaBay, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F2 · ownership.nature: Shares are held by Abingworth Bioventures VI, LP ("ABV VI") and Abingworth Bioequities Master Fund Limited ("ABE" and collectively with ABV VI the "Abingworth Funds"). Abingworth LLP ("Abingworth") is the investment manager of the Abingworth Funds and has been delegated with all investment and dispositive power over the securities held by the Abingworth Funds. The Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document
October 02, 2017 Filed Oct 4, 2017 16:02 UTC	CymaBay Therapeutics, Inc. CBAY · Entity 92768	SaleCommon Stock	37,936	$7.93	$300,832.48	Disclosure SEC source: 0000905718-17-000867 · cymabaytherafm4_oct22017.xml · nonDerivative · entry 1 EMSTER KURT VON · CIK 0001252524 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,350,940 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.83 to $8.07 per share, inclusive. Kurt von Emster (the "Reporting Person") undertakes to provide to CymaBay Therapeutics, Inc. ("CymaBay"), any security holder of CymaBay, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F2 · ownership.nature: Shares are held by Abingworth Bioventures VI, LP ("ABV VI") and Abingworth Bioequities Master Fund Limited ("ABE" and collectively with ABV VI the "Abingworth Funds"). Abingworth LLP ("Abingworth") is the investment manager of the Abingworth Funds and has been delegated with all investment and dispositive power over the securities held by the Abingworth Funds. The Reporting Person is a member of the investment committee of Abingworth LLP, which approves investment and voting decisions by a majority vote, and no individual member has the sole control or voting power over the shares held by Abingworth. The Reporting Person disclaims beneficial ownership of such shares, except to the extent of his pecuniary interest therein. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.